Mounjaro FAQ: The Questions People Ask Google

Mounjaro has changed more in the last twelve months than in its first three years. It picked up a pediatric indication, a cardiovascular indication, two new devices and a published list price. Here are the questions people actually type, answered from the current FDA label and Eli Lilly’s own published information.

None of this is medical advice. It describes what the label says and what things cost. Whether Mounjaro is right for you, and at what dose, is a conversation for you and a healthcare provider.

What is Mounjaro used for?

As of its August 2026 label, Mounjaro has two indications [1]:

1. Blood sugar control. As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes.
2. Cardiovascular risk. To reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes who are at high risk for these events.

Weight loss is not one of them. Tirzepatide, the drug in Mounjaro, is also sold as Zepbound, and Zepbound is the brand approved for chronic weight management and for obstructive sleep apnea. Same molecule, different label.

Both labels also carry the same limitation of use: taking Mounjaro alongside another tirzepatide product or any GLP-1 receptor agonist is not recommended [1].

What is Mounjaro, chemically?

Tirzepatide is a single molecule that activates two hormone receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) [1]. That dual action distinguishes it from semaglutide — the drug in Ozempic and Wegovy — and from dulaglutide, the drug in Lilly’s older Trulicity, both of which act on GLP-1 alone.

It is injected under the skin once a week, at any time of day, with or without meals [1].

Can children take Mounjaro?

Yes, from age 10. FDA approved the pediatric expansion on December 19, 2025 [2].

Some coverage dated this to February 2026, but the FDA approval letter is dated December 19, 2025. The supplement, NDA 215866/S-039, closed out a postmarketing requirement that had been attached to the original 2022 Mounjaro approval: FDA had required Lilly to run a 30-week placebo-controlled study in patients aged 10 to 17, followed by a 22-week open-label extension [2].

That study, SURPASS-PEDS, enrolled 99 patients whose type 2 diabetes was not well controlled on metformin, basal insulin or both. Mean age was 15, 61 percent were female, mean HbA1c was 8.0 percent and mean BMI was 35 [1]. At week 30 [1]:

	Placebo	Mounjaro 5 mg	Mounjaro 10 mg
HbA1c change	-0.2%	-1.9%	-2.2%
Reached HbA1c of 6.5% or lower	28%	68%	81%
BMI change	-0.5%	-6.9%	-10.8%

The label sets the maximum pediatric dose at 10 mg once weekly, compared with 15 mg in adults, and states that safety and effectiveness have not been established in children under 10 [1].

One safety note from the label: adverse reactions in pediatric patients were similar to adults, with the exception of a higher rate of vomiting, abdominal pain and hypoglycemia [1].

Does Mounjaro reduce heart attack and stroke risk?

The label now says it does, but the claim is narrower than the headlines suggest.

FDA approved the cardiovascular indication on August 27, 2026, and Lilly announced it the next day [3][4]. The approval came from SURPASS-CVOT, which Lilly describes as the first cardiovascular outcomes trial comparing two incretin medicines head-to-head rather than against a placebo [4].

The design: 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, randomized 1:1 across 640 sites in 30 countries to tirzepatide (up to 15 mg or maximum tolerated dose) or dulaglutide 1.5 mg — the drug in Trulicity, which already carried a proven cardiovascular benefit. Mean age 64, mean diabetes duration 15 years, mean HbA1c 8.4 percent [1][4].

The results over a median follow-up of 210.1 weeks, roughly four years [1]:

Outcome	Dulaglutide (n=6,647)	Mounjaro (n=6,647)	Hazard ratio
MACE-3 (CV death, non-fatal MI or non-fatal stroke)	863 (13.0%)	803 (12.1%)	0.92 (95.3% CI 0.83–1.01)
Cardiovascular death	409 (6.2%)	367 (5.5%)	0.89
Non-fatal heart attack	310 (4.7%)	292 (4.4%)	0.93
Non-fatal stroke	221 (3.3%)	215 (3.2%)	0.97
All-cause death	670 (10.1%)	567 (8.5%)	0.84 (0.75–0.94)

Read that carefully. Mounjaro met the trial’s goal of non-inferiority to dulaglutide, with a p-value of 0.007. Superiority to dulaglutide was not established — the label says so explicitly [1]. The all-cause death result looks striking, but the label flags it as not controlled for family-wise type I error, meaning it should be treated as supportive rather than definitive.

So what the approval says is that Mounjaro belongs in the same category as a GLP-1 with established cardiovascular benefit, not that it beat one.

How does the dose work?

The label states [1]:

• Start at 2.5 mg once weekly
• If additional glycemic control is needed, increase in 2.5 mg increments after at least 4 weeks on the current dose
• Maximum: 15 mg in adults, 10 mg in patients 10 years and older

One thing changed here in August 2026 and most secondary coverage has not caught up. Until then, the Mounjaro label said flatly that “the 2.5 mg dosage is for treatment initiation and is not intended for glycemic control,” and directed an increase to 5 mg after four weeks. Supplement S-045, approved alongside the heart indication on August 27, 2026, removed that sentence: FDA’s approval letter describes the change as updating the label “to indicate that the 2.5 mg dose of tirzepatide can be used for ongoing glycemic control in patients with type 2 diabetes” [11]. So on the current Mounjaro label, 2.5 mg can be a dose someone stays on. That is the opposite of the Zepbound label, which still says 2.5 mg is for initiation and is not approved as a maintenance dosage. Whether any particular dose is right for you is a question for your prescriber.

Available strengths are 2.5, 5, 7.5, 10, 12.5 and 15 mg [1].

Injection sites are the abdomen, the thigh, or — if someone else is injecting — the back of the upper arm. Rotate sites with each dose. Do not mix insulin and Mounjaro in the same injection, though both can go in the same body area as long as they are not right next to each other [1].

What if I miss a dose or want to change my injection day?

The label’s language is precise [1]:

• If a dose is missed, take it as soon as possible within 4 days (96 hours) after the missed dose
• If more than 4 days have passed, skip it and take the next dose on the regularly scheduled day
• Either way, resume the regular once-weekly schedule
• The day of weekly administration can be changed if necessary, as long as at least 3 days (72 hours) separate the two doses

What devices does Mounjaro come in?

Four, as of 2026 [1]:

• Single-dose prefilled pen, four per carton, needle built in. The standard presentation.
• Single-dose vial, one per carton. Needs your own needle and syringe.
• Multi-dose vial, four 0.6 mL doses in one 2.4 mL vial. Approved January 7, 2026.
• Single-patient-use KwikPen, four weekly doses in one pen. Approved January 20, 2026.

The KwikPen had a long road: Lilly filed the application on September 28, 2023, FDA sent an action letter on January 29, 2025, and Lilly’s complete response arrived December 2, 2025 [5].

Availability lags approval. Lilly’s own cash-pay page currently offers only the Mounjaro single-dose prefilled pen [6]. If you want a vial or KwikPen, ask your pharmacy whether they stock it.

How much does Mounjaro cost?

Three different numbers, depending on how you pay.

List price. Lilly publishes it as $1,112.16 per fill, where a fill is a month’s supply of four pens. The figure comes from AnalySource data as of January 1, 2026 [7]. Almost nobody pays this.

Cash price through LillyDirect. Lilly lists “starting at $499/month” for the single-dose pen, at every strength from 2.5 mg to 15 mg [6]. Prescriptions go to LillyDirect Pharmacy (NPI 1912889320, NCPDP 1574056), and one of four dispensing pharmacies — Amazon Pharmacy, Fuze Health, Gifthealth or Walmart Pharmacy — fills it, with free home delivery or free retail pickup [6].

With commercial insurance. The Mounjaro Single-Dose Pen Savings Card can bring eligible patients whose plan covers Mounjaro to as little as $25 for a one-, two- or three-month fill. The caps matter: maximum savings of $150, $300 or $450 per fill, and $1,950 per calendar year, for up to 13 fills. If your commercial plan does not cover Mounjaro, the card sets the price at as low as $499 a month, with maximum savings of $647 monthly and $8,411 annually. The card expires December 31, 2026 [8].

Anyone enrolled in Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE or a state prescription assistance program is excluded from the savings card [8].

Medicare and Medicaid. Under the November 2025 federal pricing agreement, injectable Mounjaro is priced at $245 a month for Medicare and state Medicaid programs, with a $50 monthly copay for Medicare beneficiaries. Mounjaro is not one of the products covered by the separate CMS Medicare GLP-1 Bridge demonstration, which names only Foundayo, Wegovy and the Zepbound KwikPen.

TrumpRx. Mounjaro is listed on the federal TrumpRx site at $499 a month against an “Original Price” of $1,112.16, a 55 percent reduction. TrumpRx does not dispense it; the site hands the order to LillyDirect, so the price matches the LillyDirect self-pay listing rather than undercutting it.

One practical tip from Lilly’s own page: many pharmacies default to a one-month quantity even when a three-month prescription is written, and many plans restrict 90-day fills. Lilly publishes a five-step checklist for getting the three-month price, which starts with asking your prescriber whether a three-month prescription makes sense and then confirming with both the pharmacy and the insurer before you go [8].

How should I store it?

The rule depends entirely on which device you have [1]:

Single-dose pen or single-dose vial. Refrigerate at 2 to 8 degrees C (36 to 46 degrees F). Each one can be kept unrefrigerated at no more than 30 degrees C (86 degrees F) for up to a total of 21 days, then discarded.

Multi-dose vial or KwikPen, unopened. Refrigerated, usable until the expiration date. At room temperature, throw away after 30 days.

Multi-dose vial or KwikPen, in use. Keep in the original carton, refrigerated or at room temperature. Throw away after a total of 30 days at room temperature, 30 days after first use, or four weekly doses — whichever comes first — even if medicine is left.

For every presentation: do not freeze, protect from heat and light, keep in the original carton, and check that the liquid is clear and colorless to slightly yellow before using it [1].

Two things worth remembering when you travel. The room-temperature budget is cumulative, so a pen that already spent a week on your kitchen counter has 14 days left, not 21. And the carton matters, because the label specifically tells you to store the product in it.

What are the warnings?

Mounjaro carries a boxed warning: in both male and female rats, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. Whether it does the same in humans is unknown, because the human relevance of the rodent finding has not been determined [1].

It is contraindicated in [1]:

• Anyone with a personal or family history of medullary thyroid carcinoma
• Anyone with Multiple Endocrine Neoplasia syndrome type 2
• Anyone with a known serious hypersensitivity to tirzepatide or any ingredient in Mounjaro

Other warnings in the label cover acute pancreatitis, hypoglycemia when combined with insulin or an insulin secretagogue such as a sulfonylurea, hypersensitivity reactions including anaphylaxis and angioedema, acute kidney injury from dehydration, severe gastrointestinal reactions (the label says Mounjaro is not recommended in people with severe gastroparesis), worsening of existing diabetic retinopathy, acute gallbladder disease, and the risk of food entering the lungs during procedures using anesthesia or deep sedation [1].

The most common adverse reactions, reported in at least 5 percent of patients, are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain [1].

Two more label items people ask about. Mounjaro delays stomach emptying, which can affect how other oral medicines are absorbed. And the label advises anyone using oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose increase [1].

How do I know my Mounjaro is real?

Lilly runs a free authenticity checker at scan.lilly.com. You scan the 2D barcode printed on the outside of the package with a smartphone, and the site checks whether the serial number is consistent with medicine manufactured by Lilly and obtained in the United States. Individual pens and vials cannot be scanned — only the package [9].

Beyond that, Lilly warns that products sold online as “tirzepatide” have been found to contain bacteria, high impurity levels, a pink color instead of the clear-to-slightly-yellow real thing, or a completely different chemical structure [10]. Tirzepatide has also never been approved as a pill, an under-the-tongue product or a nasal spray; none of those formats were studied in the trials behind Mounjaro [10].

FDA declared the tirzepatide shortage resolved in December 2024, which removed the legal basis for mass compounding of tirzepatide copies. Anything still being sold as “personalized” or “tailored” tirzepatide sits outside the approved supply chain [10].

Is there an app or support program?

Lilly offers a free Lilly Health app that stores savings card information, tracks weekly doses, charts progress and syncs with other health apps and devices. Lilly states it is not intended to make treatment decisions or replace a healthcare provider [8].

There is also a free digital starter kit, reachable by texting “MJ” to 85099 [8].

Sources

1. MOUNJARO (tirzepatide) injection and MOUNJARO KWIKPEN — US Prescribing Information, revised 8/2026 (DailyMed)
2. FDA supplement approval letter, NDA 215866/S-039 (Mounjaro pediatric indication), December 19, 2025
3. Drugs@FDA: NDA 215866 (Mounjaro) approval history
4. FDA approves Lilly’s Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes — Eli Lilly, August 28, 2026
5. FDA supplement approval letter, NDA 215866/S-009 (Mounjaro KwikPen), January 20, 2026
6. Authentic Mounjaro (tirzepatide) Shipped to You — LillyDirect
7. Mounjaro Cost Information — Eli Lilly pricing site
8. Savings and Coverage — Mounjaro (tirzepatide)
9. Check the Authenticity of Your Zepbound and Mounjaro Medication — scan.lilly.com
10. Identify Real Lilly Medicine — Eli Lilly
11. FDA supplement approval letter, NDA 215866/S-044 and S-045 (Mounjaro cardiovascular indication and 2.5 mg ongoing glycemic control), August 27, 2026